Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man

Pietro Amedeo Modesti; Alberto Fortini; Loredana Poggesi; Maria Boddi; Rosanna Abbate; Gian Franco Gensini

doi:10.1016/0049-3848(87)90432-4

Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man

Pietro Amedeo Modesti, Alberto Fortini, Loredana Poggesi, Maria Boddi, Rosanna Abbate, Gian Franco Gensini

Fondazione Don Carlo Gnocchi Onlus

Research output: Contribution to journal › Article › peer-review

Abstract

Platelet sensitivity to PGI2 and platelet PGI2 receptors were investigated in eight subjects with peripheral artery disease (stage IV according to Fontaine) treated for 14 consecutive days with six hour iv infusion of Iloprost (Schering, FRG) 2 ng/Kg/min. Platelet studies were performed on the 1st, the 2nd, the 7th and the 14th day of therapy, immediately before infusion (between 8.00 and 9.00 a.m.), at the end and 6 and 18 hours (the following morning) after the end of the infusion. Platelet sensitivity to PGI2 was assessed by determining the PGI2 inhibitory dose 50(ID 50) on platelet aggregation induced by 5 μM ADP. PGI2 platelet receptors were investigated by a direct radioligand binding assay. PGI2 ID 50 after the infusion was significantly higher than that at baseline(p

Original language	English
Pages (from-to)	663-669
Number of pages	7
Journal	Thrombosis Research
Volume	48
Issue number	6
DOIs	https://doi.org/10.1016/0049-3848(87)90432-4
Publication status	Published - Dec 15 1987

Keywords

down-regulation
Iloprost
prostacyclin
receptor

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Hematology

Access to Document

10.1016/0049-3848(87)90432-4

Fingerprint Dive into the research topics of 'Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man'. Together they form a unique fingerprint.

Cite this

@article{521e4c780e2d4d61817bbba5d7da41f3,

title = "Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man",

abstract = "Platelet sensitivity to PGI2 and platelet PGI2 receptors were investigated in eight subjects with peripheral artery disease (stage IV according to Fontaine) treated for 14 consecutive days with six hour iv infusion of Iloprost (Schering, FRG) 2 ng/Kg/min. Platelet studies were performed on the 1st, the 2nd, the 7th and the 14th day of therapy, immediately before infusion (between 8.00 and 9.00 a.m.), at the end and 6 and 18 hours (the following morning) after the end of the infusion. Platelet sensitivity to PGI2 was assessed by determining the PGI2 inhibitory dose 50(ID 50) on platelet aggregation induced by 5 μM ADP. PGI2 platelet receptors were investigated by a direct radioligand binding assay. PGI2 ID 50 after the infusion was significantly higher than that at baseline(p",

keywords = "down-regulation, Iloprost, prostacyclin, receptor",

author = "Modesti, {Pietro Amedeo} and Alberto Fortini and Loredana Poggesi and Maria Boddi and Rosanna Abbate and Gensini, {Gian Franco}",

year = "1987",

month = dec,

day = "15",

doi = "10.1016/0049-3848(87)90432-4",

language = "English",

volume = "48",

pages = "663--669",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man

AU - Modesti, Pietro Amedeo

AU - Fortini, Alberto

AU - Poggesi, Loredana

AU - Boddi, Maria

AU - Abbate, Rosanna

AU - Gensini, Gian Franco

PY - 1987/12/15

Y1 - 1987/12/15

N2 - Platelet sensitivity to PGI2 and platelet PGI2 receptors were investigated in eight subjects with peripheral artery disease (stage IV according to Fontaine) treated for 14 consecutive days with six hour iv infusion of Iloprost (Schering, FRG) 2 ng/Kg/min. Platelet studies were performed on the 1st, the 2nd, the 7th and the 14th day of therapy, immediately before infusion (between 8.00 and 9.00 a.m.), at the end and 6 and 18 hours (the following morning) after the end of the infusion. Platelet sensitivity to PGI2 was assessed by determining the PGI2 inhibitory dose 50(ID 50) on platelet aggregation induced by 5 μM ADP. PGI2 platelet receptors were investigated by a direct radioligand binding assay. PGI2 ID 50 after the infusion was significantly higher than that at baseline(p

AB - Platelet sensitivity to PGI2 and platelet PGI2 receptors were investigated in eight subjects with peripheral artery disease (stage IV according to Fontaine) treated for 14 consecutive days with six hour iv infusion of Iloprost (Schering, FRG) 2 ng/Kg/min. Platelet studies were performed on the 1st, the 2nd, the 7th and the 14th day of therapy, immediately before infusion (between 8.00 and 9.00 a.m.), at the end and 6 and 18 hours (the following morning) after the end of the infusion. Platelet sensitivity to PGI2 was assessed by determining the PGI2 inhibitory dose 50(ID 50) on platelet aggregation induced by 5 μM ADP. PGI2 platelet receptors were investigated by a direct radioligand binding assay. PGI2 ID 50 after the infusion was significantly higher than that at baseline(p

KW - down-regulation

KW - Iloprost

KW - prostacyclin

KW - receptor

UR - http://www.scopus.com/inward/record.url?scp=0023613574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023613574&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(87)90432-4

DO - 10.1016/0049-3848(87)90432-4

M3 - Article

C2 - 2448896

AN - SCOPUS:0023613574

VL - 48

SP - 663

EP - 669

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -